JP2010505396A - リボ核酸を抽出するための安定化組成物および方法 - Google Patents
リボ核酸を抽出するための安定化組成物および方法 Download PDFInfo
- Publication number
- JP2010505396A JP2010505396A JP2009530744A JP2009530744A JP2010505396A JP 2010505396 A JP2010505396 A JP 2010505396A JP 2009530744 A JP2009530744 A JP 2009530744A JP 2009530744 A JP2009530744 A JP 2009530744A JP 2010505396 A JP2010505396 A JP 2010505396A
- Authority
- JP
- Japan
- Prior art keywords
- acid
- rna
- composition
- sample
- weeks
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 216
- 229920002477 rna polymer Polymers 0.000 title claims abstract description 207
- 238000000034 method Methods 0.000 title claims abstract description 70
- 239000000523 sample Substances 0.000 claims abstract description 160
- 239000000872 buffer Substances 0.000 claims abstract description 38
- 239000003945 anionic surfactant Substances 0.000 claims abstract description 22
- 230000000087 stabilizing effect Effects 0.000 claims abstract description 13
- 239000012472 biological sample Substances 0.000 claims abstract description 11
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 57
- 241000700605 Viruses Species 0.000 claims description 30
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 27
- 241000283690 Bos taurus Species 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 24
- 238000003860 storage Methods 0.000 claims description 19
- 108010067770 Endopeptidase K Proteins 0.000 claims description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 16
- 108700004121 sarkosyl Proteins 0.000 claims description 16
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 claims description 15
- 238000010438 heat treatment Methods 0.000 claims description 14
- 210000001124 body fluid Anatomy 0.000 claims description 13
- 241000894006 Bacteria Species 0.000 claims description 12
- 238000012545 processing Methods 0.000 claims description 11
- 229940016590 sarkosyl Drugs 0.000 claims description 11
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 claims description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- 244000005700 microbiome Species 0.000 claims description 9
- 241001494479 Pecora Species 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- 241000282887 Suidae Species 0.000 claims description 7
- 244000144977 poultry Species 0.000 claims description 7
- 235000013594 poultry meat Nutrition 0.000 claims description 7
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 claims description 6
- SXGZJKUKBWWHRA-UHFFFAOYSA-N 2-(N-morpholiniumyl)ethanesulfonate Chemical compound [O-]S(=O)(=O)CC[NH+]1CCOCC1 SXGZJKUKBWWHRA-UHFFFAOYSA-N 0.000 claims description 6
- 241000251468 Actinopterygii Species 0.000 claims description 6
- 241000272517 Anseriformes Species 0.000 claims description 6
- 241000283707 Capra Species 0.000 claims description 6
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 claims description 6
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 claims description 6
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 claims description 6
- 241000286209 Phasianidae Species 0.000 claims description 6
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 6
- OGGXGZAMXPVRFZ-UHFFFAOYSA-N dimethylarsinic acid Chemical compound C[As](C)(O)=O OGGXGZAMXPVRFZ-UHFFFAOYSA-N 0.000 claims description 6
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000001632 sodium acetate Substances 0.000 claims description 6
- 235000017281 sodium acetate Nutrition 0.000 claims description 6
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 claims description 6
- 241000282472 Canis lupus familiaris Species 0.000 claims description 5
- 241000282994 Cervidae Species 0.000 claims description 5
- 241000282326 Felis catus Species 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 241000287828 Gallus gallus Species 0.000 claims description 4
- 235000013330 chicken meat Nutrition 0.000 claims description 4
- 244000045947 parasite Species 0.000 claims description 4
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000010865 sewage Substances 0.000 claims description 4
- 239000002689 soil Substances 0.000 claims description 4
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 claims description 3
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 claims description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 claims description 3
- 239000007991 ACES buffer Substances 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 3
- 241000282979 Alces alces Species 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 3
- 241000700198 Cavia Species 0.000 claims description 3
- 241000699800 Cricetinae Species 0.000 claims description 3
- 241000699694 Gerbillinae Species 0.000 claims description 3
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 3
- 241000270322 Lepidosauria Species 0.000 claims description 3
- 241000699670 Mus sp. Species 0.000 claims description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 3
- 108091005804 Peptidases Proteins 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000004365 Protease Substances 0.000 claims description 3
- 241000700159 Rattus Species 0.000 claims description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 3
- 241000283984 Rodentia Species 0.000 claims description 3
- 241000270295 Serpentes Species 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- 241000270666 Testudines Species 0.000 claims description 3
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 3
- 239000007983 Tris buffer Substances 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 3
- 238000010171 animal model Methods 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- 229950004243 cacodylic acid Drugs 0.000 claims description 3
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 claims description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 3
- 229960002885 histidine Drugs 0.000 claims description 3
- YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229940098895 maleic acid Drugs 0.000 claims description 3
- 239000001630 malic acid Substances 0.000 claims description 3
- 235000011090 malic acid Nutrition 0.000 claims description 3
- 244000000010 microbial pathogen Species 0.000 claims description 3
- 235000019419 proteases Nutrition 0.000 claims description 3
- 229940005657 pyrophosphoric acid Drugs 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- HRQDCDQDOPSGBR-UHFFFAOYSA-M sodium;octane-1-sulfonate Chemical compound [Na+].CCCCCCCCS([O-])(=O)=O HRQDCDQDOPSGBR-UHFFFAOYSA-M 0.000 claims description 3
- OFYLYBVZQCOXRQ-UHFFFAOYSA-J tetrasodium;cyclohexane-1,1-diamine;tetraacetate Chemical group [Na+].[Na+].[Na+].[Na+].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.NC1(N)CCCCC1 OFYLYBVZQCOXRQ-UHFFFAOYSA-J 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 108010077895 Sarcosine Proteins 0.000 claims description 2
- 229940043230 sarcosine Drugs 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 6
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 claims 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims 4
- 239000007853 buffer solution Substances 0.000 claims 3
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 claims 3
- DJHGAFSJWGLOIV-UHFFFAOYSA-N Arsenic acid Chemical compound O[As](O)(O)=O DJHGAFSJWGLOIV-UHFFFAOYSA-N 0.000 claims 2
- 241000282458 Ursus sp. Species 0.000 claims 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims 2
- 229940000488 arsenic acid Drugs 0.000 claims 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims 2
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 235000006408 oxalic acid Nutrition 0.000 claims 2
- 239000008363 phosphate buffer Substances 0.000 claims 1
- 239000008055 phosphate buffer solution Substances 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 description 140
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 59
- 150000007523 nucleic acids Chemical class 0.000 description 50
- 102000039446 nucleic acids Human genes 0.000 description 49
- 108020004707 nucleic acids Proteins 0.000 description 49
- 102000006382 Ribonucleases Human genes 0.000 description 37
- 108010083644 Ribonucleases Proteins 0.000 description 37
- 108020004635 Complementary DNA Proteins 0.000 description 34
- 238000010804 cDNA synthesis Methods 0.000 description 34
- 239000002299 complementary DNA Substances 0.000 description 34
- 238000010240 RT-PCR analysis Methods 0.000 description 31
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 30
- 229960005542 ethidium bromide Drugs 0.000 description 30
- 210000004027 cell Anatomy 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 26
- 102000053602 DNA Human genes 0.000 description 26
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 26
- 238000004458 analytical method Methods 0.000 description 24
- 239000013615 primer Substances 0.000 description 24
- 210000001519 tissue Anatomy 0.000 description 24
- 238000010839 reverse transcription Methods 0.000 description 22
- 208000015181 infectious disease Diseases 0.000 description 21
- 238000001962 electrophoresis Methods 0.000 description 20
- 239000011543 agarose gel Substances 0.000 description 19
- 238000001514 detection method Methods 0.000 description 19
- 239000006260 foam Substances 0.000 description 19
- 210000003928 nasal cavity Anatomy 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 238000000746 purification Methods 0.000 description 16
- 108020004463 18S ribosomal RNA Proteins 0.000 description 15
- 108020004999 messenger RNA Proteins 0.000 description 15
- 239000002244 precipitate Substances 0.000 description 15
- 210000000214 mouth Anatomy 0.000 description 14
- 239000007788 liquid Substances 0.000 description 13
- 239000001103 potassium chloride Substances 0.000 description 13
- 235000011164 potassium chloride Nutrition 0.000 description 13
- 102100034343 Integrase Human genes 0.000 description 12
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- 102000016911 Deoxyribonucleases Human genes 0.000 description 11
- 108010053770 Deoxyribonucleases Proteins 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 239000010839 body fluid Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 239000000126 substance Substances 0.000 description 10
- 229920000742 Cotton Polymers 0.000 description 9
- 241000712079 Measles morbillivirus Species 0.000 description 9
- 206010036790 Productive cough Diseases 0.000 description 9
- 238000011534 incubation Methods 0.000 description 9
- 210000001331 nose Anatomy 0.000 description 9
- 108020004418 ribosomal RNA Proteins 0.000 description 9
- 238000005070 sampling Methods 0.000 description 9
- 210000003802 sputum Anatomy 0.000 description 9
- 208000024794 sputum Diseases 0.000 description 9
- 230000002458 infectious effect Effects 0.000 description 8
- 210000003097 mucus Anatomy 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000013641 positive control Substances 0.000 description 8
- 230000000241 respiratory effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000003612 virological effect Effects 0.000 description 8
- 239000013614 RNA sample Substances 0.000 description 7
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 7
- 108020000999 Viral RNA Proteins 0.000 description 7
- 238000000246 agarose gel electrophoresis Methods 0.000 description 7
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000015556 catabolic process Effects 0.000 description 7
- 238000006731 degradation reaction Methods 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 210000002850 nasal mucosa Anatomy 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000032258 transport Effects 0.000 description 7
- 208000035473 Communicable disease Diseases 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 108010006785 Taq Polymerase Proteins 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 235000013365 dairy product Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000464 low-speed centrifugation Methods 0.000 description 6
- 210000003800 pharynx Anatomy 0.000 description 6
- 238000012340 reverse transcriptase PCR Methods 0.000 description 6
- 241000894007 species Species 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 239000006163 transport media Substances 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000029742 colonic neoplasm Diseases 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 208000000592 Nasal Polyps Diseases 0.000 description 4
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 4
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 241000711975 Vesicular stomatitis virus Species 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000007710 freezing Methods 0.000 description 4
- 230000008014 freezing Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000004877 mucosa Anatomy 0.000 description 4
- 208000016366 nasal cavity polyp Diseases 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000233866 Fungi Species 0.000 description 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical class NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 241000711798 Rabies lyssavirus Species 0.000 description 3
- 206010039101 Rhinorrhoea Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 241001493065 dsRNA viruses Species 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000010753 nasal discharge Diseases 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- XNYQOAOGCKKCNI-UHFFFAOYSA-L oxalate;trimethyl(tetradecyl)azanium Chemical compound [O-]C(=O)C([O-])=O.CCCCCCCCCCCCCC[N+](C)(C)C.CCCCCCCCCCCCCC[N+](C)(C)C XNYQOAOGCKKCNI-UHFFFAOYSA-L 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000006641 stabilisation Effects 0.000 description 3
- 238000011105 stabilization Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 210000002700 urine Anatomy 0.000 description 3
- 238000003260 vortexing Methods 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241001519465 Avian metapneumovirus Species 0.000 description 2
- 241000714266 Bovine leukemia virus Species 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 208000002979 Influenza in Birds Diseases 0.000 description 2
- 201000005505 Measles Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000315672 SARS coronavirus Species 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 239000012491 analyte Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 206010064097 avian influenza Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 150000001767 cationic compounds Chemical class 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000013129 endoscopic sinus surgery Methods 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000003607 modifier Substances 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 238000001821 nucleic acid purification Methods 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000004713 phosphodiesters Chemical group 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000012521 purified sample Substances 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000001533 respiratory mucosa Anatomy 0.000 description 2
- 238000002435 rhinoplasty Methods 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229940034610 toothpaste Drugs 0.000 description 2
- 239000000606 toothpaste Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- NLOGSHMIAWCODV-UHFFFAOYSA-N 2-piperazin-4-ium-1-ylethanesulfonate Chemical compound OS(=O)(=O)CCN1CCNCC1 NLOGSHMIAWCODV-UHFFFAOYSA-N 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N 5,5-diethylbarbituric acid Chemical compound CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- DJHGAFSJWGLOIV-UHFFFAOYSA-K Arsenate3- Chemical compound [O-][As]([O-])([O-])=O DJHGAFSJWGLOIV-UHFFFAOYSA-K 0.000 description 1
- 208000034048 Asymptomatic disease Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 241000711443 Bovine coronavirus Species 0.000 description 1
- 241000712005 Bovine respirovirus 3 Species 0.000 description 1
- 241000710780 Bovine viral diarrhea virus 1 Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000002494 Endoribonucleases Human genes 0.000 description 1
- 108010093099 Endoribonucleases Proteins 0.000 description 1
- 241000710803 Equine arteritis virus Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 125000002066 L-histidyl group Chemical group [H]N1C([H])=NC(C([H])([H])[C@](C(=O)[*])([H])N([H])[H])=C1[H] 0.000 description 1
- 238000007397 LAMP assay Methods 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108020003217 Nuclear RNA Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 description 1
- 241000711493 Porcine respiratory coronavirus Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000013616 RNA primer Substances 0.000 description 1
- 230000021839 RNA stabilization Effects 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010051497 Rhinotracheitis Diseases 0.000 description 1
- 101710141795 Ribonuclease inhibitor Proteins 0.000 description 1
- 229940122208 Ribonuclease inhibitor Drugs 0.000 description 1
- 102100037968 Ribonuclease inhibitor Human genes 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229940000489 arsenate Drugs 0.000 description 1
- 229960002319 barbital Drugs 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000002144 chemical decomposition reaction Methods 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- -1 cyclohexanediaminetetraacetic acid sodium salt Chemical class 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 108091092330 cytoplasmic RNA Proteins 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003398 denaturant Substances 0.000 description 1
- 229940119679 deoxyribonucleases Drugs 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000005252 hepatitis A Diseases 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 108091064355 mitochondrial RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 230000016379 mucosal immune response Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 210000001819 pancreatic juice Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- 239000013014 purified material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 210000003705 ribosome Anatomy 0.000 description 1
- 235000002020 sage Nutrition 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000009589 serological test Methods 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000003670 sublingual gland Anatomy 0.000 description 1
- 210000001913 submandibular gland Anatomy 0.000 description 1
- 235000021092 sugar substitutes Nutrition 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000002351 wastewater Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82856306P | 2006-10-06 | 2006-10-06 | |
| US86698506P | 2006-11-22 | 2006-11-22 | |
| US94977807P | 2007-07-13 | 2007-07-13 | |
| PCT/CA2007/001785 WO2008040126A1 (en) | 2006-10-06 | 2007-10-05 | Stabilizing compositions and methods for extraction of ribonucleic acid |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013229632A Division JP2014057590A (ja) | 2006-10-06 | 2013-11-05 | リボ核酸を抽出するための方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010505396A true JP2010505396A (ja) | 2010-02-25 |
| JP2010505396A5 JP2010505396A5 (enExample) | 2012-02-16 |
Family
ID=39268089
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009530744A Pending JP2010505396A (ja) | 2006-10-06 | 2007-10-05 | リボ核酸を抽出するための安定化組成物および方法 |
| JP2013229632A Pending JP2014057590A (ja) | 2006-10-06 | 2013-11-05 | リボ核酸を抽出するための方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013229632A Pending JP2014057590A (ja) | 2006-10-06 | 2013-11-05 | リボ核酸を抽出するための方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (4) | US20100099149A1 (enExample) |
| EP (1) | EP2066686A4 (enExample) |
| JP (2) | JP2010505396A (enExample) |
| AU (1) | AU2007304776A1 (enExample) |
| CA (1) | CA2664696C (enExample) |
| IL (1) | IL197916A (enExample) |
| NZ (1) | NZ576003A (enExample) |
| SG (1) | SG179454A1 (enExample) |
| WO (1) | WO2008040126A1 (enExample) |
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013002354A1 (ja) * | 2011-06-29 | 2013-01-03 | 株式会社ダナフォーム | 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット |
| JP2014198029A (ja) * | 2013-03-29 | 2014-10-23 | ソニー株式会社 | 核酸増幅反応用試料の調製方法、核酸増幅方法、固相状核酸増幅反応用試薬及びマイクロチップ |
| JP2016049076A (ja) * | 2014-09-02 | 2016-04-11 | 国立大学法人 鹿児島大学 | 染色体キメラの検出方法 |
| JP2017508478A (ja) * | 2014-03-07 | 2017-03-30 | ディーエヌエー ジェノテック インク | 生物試料中の核酸を安定化する組成物および方法 |
| WO2017073767A1 (ja) * | 2015-10-30 | 2017-05-04 | 株式会社ボナック | ＴＧＦ－β１遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物 |
| JP2017516477A (ja) * | 2014-05-27 | 2017-06-22 | ディーエヌエー ジェノテック インク | 頑丈な微生物の生存能力を安定化および維持するための組成物および方法 |
| JP2017536813A (ja) * | 2014-10-20 | 2017-12-14 | エンバイロロジックス インコーポレイテッド | Ｒｎａウイルスを検出するための組成物及び方法 |
| US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| US11505836B2 (en) | 2014-04-22 | 2022-11-22 | Envirologix Inc. | Compositions and methods for enhancing and/or predicting DNA amplification |
| US11866773B2 (en) | 2012-04-09 | 2024-01-09 | Envirologix Inc. | Isolated oligonucleotides containing modified nucleotides |
| US12043866B2 (en) | 2010-08-13 | 2024-07-23 | Envirologix Inc. | Compositions and methods for quantifying a nucleic acid sequence in a sample |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7482116B2 (en) | 2002-06-07 | 2009-01-27 | Dna Genotek Inc. | Compositions and methods for obtaining nucleic acids from sputum |
| EP1737573A2 (en) | 2004-04-08 | 2007-01-03 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
| ATE531311T1 (de) | 2005-12-09 | 2011-11-15 | Dna Genotek Inc | Behältersystem zur lagerung und leichten ausgabe einer substanz |
| JP2010505396A (ja) * | 2006-10-06 | 2010-02-25 | ディーエヌエー ジェノテック インク | リボ核酸を抽出するための安定化組成物および方法 |
| US8975026B2 (en) | 2007-01-16 | 2015-03-10 | Somalogic, Inc. | Method for generating aptamers with improved off-rates |
| DE102007025275A1 (de) * | 2007-05-31 | 2008-12-04 | Qiagen Gmbh | Butendisäure oder deren Derivate zur Behandlung einer biologischen Probe |
| WO2009142743A1 (en) * | 2008-05-20 | 2009-11-26 | Cantimer, Inc. | Methods, systems and devices for analyzing a surfactant-treated biological fluid sample |
| US8703416B2 (en) * | 2008-07-17 | 2014-04-22 | Somalogic, Inc. | Method for purification and identification of sperm cells |
| EP3206009B1 (en) | 2008-08-21 | 2025-05-14 | DNA Genotek Inc. | Sample receiving device |
| WO2010083844A1 (en) | 2009-01-26 | 2010-07-29 | Quantibact A/S | Methods and uses for rna extract and storage |
| CA2806670A1 (en) * | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
| CA2806734A1 (en) * | 2010-07-26 | 2012-02-09 | Biomatrica, Inc. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
| DK2742152T3 (en) * | 2011-08-12 | 2017-07-31 | Qiagen Gmbh | PROCEDURE FOR ISOLATING NUCLEIC ACIDS |
| HK1217117A1 (zh) | 2012-12-20 | 2016-12-23 | 生物马特里卡公司 | 用於使pcr试剂稳定化的制剂和方法 |
| MX368207B (es) | 2013-08-01 | 2019-09-24 | Ancestry Com Dna Llc | Dispositivo de recolección de muestras. |
| WO2015031994A1 (en) * | 2013-09-03 | 2015-03-12 | Dna Genotek Inc. | Method and composition for nucleic acid storage from blood fractions |
| WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
| WO2016144891A1 (en) | 2015-03-06 | 2016-09-15 | Bio-Rad Laboratories, Inc. | Stabilized rna solutions |
| CN108473932B (zh) | 2015-09-09 | 2022-07-15 | 集联健康有限公司 | 用于样品收集、稳定化和保存的系统、方法和装置 |
| US10905113B2 (en) | 2015-11-12 | 2021-02-02 | Regents Of The University Of Minnesota | Compositions and method for storing liquid biospecimens |
| WO2017100212A1 (en) | 2015-12-08 | 2017-06-15 | Biomatrica, Inc. | Reduction of erythrocyte sedimentation rate |
| JP6733951B2 (ja) * | 2016-05-09 | 2020-08-05 | 日本メナード化粧品株式会社 | 核酸保存用組成物及び核酸保存方法 |
| JP7572142B2 (ja) | 2016-05-31 | 2024-10-23 | ディーエヌエー ジェノテック インク | 水溶液からの洗浄剤の除去のための組成物、システムおよび方法 |
| MX2019010800A (es) | 2017-03-15 | 2020-07-28 | Ancestry Com Dna Llc | Dispositivo y metodo de recoleccion de muestras. |
| WO2019070833A1 (en) | 2017-10-06 | 2019-04-11 | Ancestry.Com Dna, Llc | SYSTEMS, DEVICES AND METHODS OF SAMPLE COLLECTION |
| US11311884B2 (en) | 2017-11-22 | 2022-04-26 | Ancestry.Com Dna, Llc | Sample collection kit including cap having selectively movable sleeve |
| US11426734B2 (en) | 2017-11-22 | 2022-08-30 | Ancestry.Com Dna, Llc | Sample collection kit including cap having selectively movable sleeve |
| AU2019221318B2 (en) | 2018-02-14 | 2025-11-27 | Salignostics Ltd. | Methods and apparatus for detecting analytes |
| JP2022511993A (ja) * | 2018-11-14 | 2022-02-01 | スペクトラム・ソリューションズ・エルエルシー | Ｒｎａ保存溶液、及び製造方法及び使用方法 |
| WO2020106891A1 (en) | 2018-11-20 | 2020-05-28 | Spectrum Solutions, Llc | Sample collection system including sealing cap and valve |
| WO2020174442A1 (en) | 2019-02-27 | 2020-09-03 | Ancestry.Com Dna, Llc | Graphical user interface displaying relatedness based on shared dna |
| US11968975B2 (en) | 2019-04-30 | 2024-04-30 | Regents Of The University Of Minnesota | Compositions and methods for storing liquid biospecimens |
| US11701094B2 (en) | 2019-06-20 | 2023-07-18 | Spectrum Solutions L.L.C. | Sample collection system including valve and plug assemblies |
| WO2021187824A1 (en) * | 2020-03-16 | 2021-09-23 | Seegene, Inc. | Sampling kit used in determination of respiratory infection |
| KR102370468B1 (ko) * | 2020-03-18 | 2022-03-03 | 재단법인대구경북과학기술원 | 생체 시료 내 잔존하는 음이온 계면 활성제와 이와 결합한 지질 또는 단백질 결합체, 및 마이셀을 제거하는 조성물, 방법 및 이의 용도 |
| EP3996732A4 (en) * | 2020-04-14 | 2022-08-24 | Spectrum Solutions, LLC | ASSAYS AND METHODS FOR DETECTION OF VIRAL NUCLEIC ACIDS |
| WO2021257844A1 (en) | 2020-06-18 | 2021-12-23 | The Board Of Trustees Of The University Of Illinois | Saliva-based molecular testing for sars-cov-2 |
| AT17544U1 (de) * | 2020-06-22 | 2022-07-15 | Lead Horizon Gmbh | Vorrichtung zur gewinnung einer rachenspülprobe |
| SK500262021A3 (sk) * | 2020-06-22 | 2022-01-26 | Lead Horizon Gmbh | Zariadenie na získanie vzorky výplachu z hltana |
| WO2022015514A1 (en) * | 2020-07-13 | 2022-01-20 | The Board Of Trustees Of The Leland Stanford Junior University | Systems and methods to enhance rna stability and translation and uses thereof |
| US11207057B1 (en) | 2020-08-07 | 2021-12-28 | Cyrano Medical, Inc. | Nasopharyngeal sample collection devices and methods |
| US11724077B2 (en) * | 2021-07-28 | 2023-08-15 | Subhash Dhawan | Therapeutic swabs for treating upper respiratory infections |
| US12332902B2 (en) | 2022-04-20 | 2025-06-17 | Ancestry.Com Dna, Llc | Filtering individual datasets in a database |
| CN121175761A (zh) * | 2023-03-16 | 2025-12-19 | 贾瓦哈拉尔·尼赫鲁纪念医学院 | 用于确定covid-19结果严重程度的体外方法和试剂盒 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522092A (ja) * | 1998-08-12 | 2002-07-23 | アンティゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血液を採取するための容器 |
| WO2003104251A2 (en) * | 2002-06-07 | 2003-12-18 | Dna Genotek Inc. | Composition and methods for obtaining nucleic acids from sputum |
| JP2006501850A (ja) * | 2002-10-04 | 2006-01-19 | ワットマン インコーポレイテッド | 核酸精製システムの媒体上に核酸を保存するツールとして、化学物質を用いる方法および材料 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935340A (en) * | 1985-06-07 | 1990-06-19 | Eli Lilly And Company | Method of isolating antibiotic biosynthetic genes |
| US5756126A (en) * | 1991-05-29 | 1998-05-26 | Flinders Technologies Pty. Ltd. | Dry solid medium for storage and analysis of genetic material |
| US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
| DE4034036C2 (de) * | 1990-10-26 | 1994-03-03 | Diagen Inst Molekularbio | Vorrichtung und Verfahren zur Isolierung von Nukleinsäuren aus Zellsuspensionen |
| US5512440A (en) * | 1991-12-18 | 1996-04-30 | Becton Dickinson And Company | Process for lysing Mycobacteria |
| AU664050B2 (en) * | 1991-12-18 | 1995-11-02 | Becton Dickinson & Company | Process for lysing mycobacteria |
| US6551791B1 (en) * | 1995-12-21 | 2003-04-22 | University Of Florida | Rapid diagnostic method for distinguishing allergies and infections and nasal secretion collection unit |
| US5973137A (en) * | 1996-02-13 | 1999-10-26 | Gentra Systems, Inc. | Low pH RNA isolation reagents, method, and kit |
| US5939262A (en) * | 1996-07-03 | 1999-08-17 | Ambion, Inc. | Ribonuclease resistant RNA preparation and utilization |
| US5939259A (en) * | 1997-04-09 | 1999-08-17 | Schleicher & Schuell, Inc. | Methods and devices for collecting and storing clinical samples for genetic analysis |
| US6071745A (en) * | 1997-06-27 | 2000-06-06 | Bio-Rad Laboratories | Method and formulation for lyophilizing cultured human cells to preserve RNA and DNA contained in cells for use in molecular biology experiments |
| US7626017B2 (en) * | 1997-10-31 | 2009-12-01 | Pressure Biosciences, Inc. | Pressure-enhanced extraction and purification |
| US7244828B2 (en) * | 1997-11-07 | 2007-07-17 | Aftab Alam | Agent for protein precipitation, a method of protein precipitation, a method of protein assay using protein precipitation agent, and a kit for protein assay |
| US6204375B1 (en) * | 1998-07-31 | 2001-03-20 | Ambion, Inc. | Methods and reagents for preserving RNA in cell and tissue samples |
| US6777210B1 (en) * | 1998-09-24 | 2004-08-17 | Ambion, Inc. | Method and reagents for inactivating ribonucleases RNase A, RNase I and RNase T1 |
| WO2001021830A1 (en) * | 1999-09-24 | 2001-03-29 | Ambion, Inc. | Nuclease inhibitor cocktail |
| US6409528B1 (en) * | 1999-12-06 | 2002-06-25 | Becton, Dickinson And Company | Device and method for collecting, preparation and stabilizing a sample |
| EP1252338B1 (de) * | 2000-02-04 | 2007-10-17 | QIAGEN GmbH | Nukleinsäure-isolierung aus stuhlproben und anderen biologischen materialien, die reich an inhibitoren sind |
| US6602718B1 (en) * | 2000-11-08 | 2003-08-05 | Becton, Dickinson And Company | Method and device for collecting and stabilizing a biological sample |
| US7029840B2 (en) * | 2000-11-15 | 2006-04-18 | Becton, Dickinson And Company | Method for preservation of cells and nucleic acid targets |
| US7001724B1 (en) * | 2000-11-28 | 2006-02-21 | Applera Corporation | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases |
| US20030170694A1 (en) * | 2001-12-21 | 2003-09-11 | Daniel Wall | Stabilized nucleic acids in gene and drug discovery and methods of use |
| DE10219117C1 (de) * | 2002-04-29 | 2003-10-30 | Adnagen Ag | Verfahren zur Stabilisierung von RNS und Verwendungen von Stabilisierungspuffern |
| AU2006225044B2 (en) | 2005-03-16 | 2012-03-15 | Dna Genotek Inc. | Compositions and method for storage of nucleic acid from bodily fluids |
| US7670849B2 (en) * | 2005-04-29 | 2010-03-02 | Henkin Robert I | Method for diagnosing insulin resistance from nasal secretions |
| US20070015165A1 (en) * | 2005-07-13 | 2007-01-18 | Sigma-Aldrich Co. | Method for the isolation of RNA from biological sources |
| ATE531311T1 (de) | 2005-12-09 | 2011-11-15 | Dna Genotek Inc | Behältersystem zur lagerung und leichten ausgabe einer substanz |
| EP1996070A2 (en) | 2006-03-17 | 2008-12-03 | The Regents of the University of California | Collection assembly for obtaining oral samples from an animal |
| JP2010505396A (ja) * | 2006-10-06 | 2010-02-25 | ディーエヌエー ジェノテック インク | リボ核酸を抽出するための安定化組成物および方法 |
-
2007
- 2007-10-05 JP JP2009530744A patent/JP2010505396A/ja active Pending
- 2007-10-05 WO PCT/CA2007/001785 patent/WO2008040126A1/en not_active Ceased
- 2007-10-05 CA CA2664696A patent/CA2664696C/en active Active
- 2007-10-05 US US12/444,447 patent/US20100099149A1/en not_active Abandoned
- 2007-10-05 NZ NZ576003A patent/NZ576003A/en unknown
- 2007-10-05 SG SG2012016606A patent/SG179454A1/en unknown
- 2007-10-05 AU AU2007304776A patent/AU2007304776A1/en not_active Abandoned
- 2007-10-05 EP EP07855412A patent/EP2066686A4/en not_active Ceased
-
2009
- 2009-04-05 IL IL197916A patent/IL197916A/en active IP Right Grant
-
2013
- 2013-11-05 JP JP2013229632A patent/JP2014057590A/ja active Pending
-
2016
- 2016-05-20 US US15/160,712 patent/US10000795B2/en active Active
-
2018
- 2018-05-15 US US15/980,682 patent/US10767215B2/en active Active
-
2020
- 2020-09-08 US US17/014,688 patent/US20210198717A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002522092A (ja) * | 1998-08-12 | 2002-07-23 | アンティゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング | 血液を採取するための容器 |
| WO2003104251A2 (en) * | 2002-06-07 | 2003-12-18 | Dna Genotek Inc. | Composition and methods for obtaining nucleic acids from sputum |
| JP2006501850A (ja) * | 2002-10-04 | 2006-01-19 | ワットマン インコーポレイテッド | 核酸精製システムの媒体上に核酸を保存するツールとして、化学物質を用いる方法および材料 |
Cited By (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12043866B2 (en) | 2010-08-13 | 2024-07-23 | Envirologix Inc. | Compositions and methods for quantifying a nucleic acid sequence in a sample |
| US11549870B2 (en) | 2011-06-19 | 2023-01-10 | DNA Genotek, Inc. | Cell preserving solution |
| US11002646B2 (en) | 2011-06-19 | 2021-05-11 | DNA Genotek, Inc. | Devices, solutions and methods for sample collection |
| US11592368B2 (en) | 2011-06-19 | 2023-02-28 | DNA Genotek, Inc. | Method for collecting and preserving a biological sample |
| US11536632B2 (en) | 2011-06-19 | 2022-12-27 | DNA Genotek, Inc. | Biological collection system |
| US9518901B2 (en) | 2011-06-29 | 2016-12-13 | Kabushiki Kaisha Dnaform | Pretreatment method of biological sample, detection method of RNA, and pretreatment kit |
| WO2013002354A1 (ja) * | 2011-06-29 | 2013-01-03 | 株式会社ダナフォーム | 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット |
| JPWO2013002354A1 (ja) * | 2011-06-29 | 2015-02-23 | 株式会社ダナフォーム | 生体試料の前処理方法、ｒｎａの検出方法及び前処理キット |
| US11866773B2 (en) | 2012-04-09 | 2024-01-09 | Envirologix Inc. | Isolated oligonucleotides containing modified nucleotides |
| JP2014198029A (ja) * | 2013-03-29 | 2014-10-23 | ソニー株式会社 | 核酸増幅反応用試料の調製方法、核酸増幅方法、固相状核酸増幅反応用試薬及びマイクロチップ |
| JP2017508478A (ja) * | 2014-03-07 | 2017-03-30 | ディーエヌエー ジェノテック インク | 生物試料中の核酸を安定化する組成物および方法 |
| US12258637B2 (en) | 2014-04-22 | 2025-03-25 | Envirologix Inc. | Compositions and methods for enhancing and/or predicting DNA amplification |
| US11505836B2 (en) | 2014-04-22 | 2022-11-22 | Envirologix Inc. | Compositions and methods for enhancing and/or predicting DNA amplification |
| JP2017516477A (ja) * | 2014-05-27 | 2017-06-22 | ディーエヌエー ジェノテック インク | 頑丈な微生物の生存能力を安定化および維持するための組成物および方法 |
| US11753616B2 (en) | 2014-05-27 | 2023-09-12 | DNA Genotek, Inc. | Composition and method for stabilizing and maintaining the viability of hardy microorganisms |
| JP2016049076A (ja) * | 2014-09-02 | 2016-04-11 | 国立大学法人 鹿児島大学 | 染色体キメラの検出方法 |
| JP2021045140A (ja) * | 2014-10-20 | 2021-03-25 | エンバイロロジックス インコーポレイテッド | Ｒｎａウイルスを検出するための組成物及び方法 |
| JP7114676B2 (ja) | 2014-10-20 | 2022-08-08 | エンバイロロジックス インコーポレイテッド | Ｒｎａウイルスを検出するための組成物及び方法 |
| US10793922B2 (en) | 2014-10-20 | 2020-10-06 | Envirologix Inc. | Compositions and methods for detecting an RNA virus |
| JP2017536813A (ja) * | 2014-10-20 | 2017-12-14 | エンバイロロジックス インコーポレイテッド | Ｒｎａウイルスを検出するための組成物及び方法 |
| US12392001B2 (en) | 2014-10-20 | 2025-08-19 | Envirologix Inc. | Compositions and methods for detecting an RNA virus |
| US10751426B2 (en) | 2015-10-30 | 2020-08-25 | Bonac Corporation | Composition stably containing single-stranded nucleic acid molecule that suppresses expression of TGF-β1 gene |
| JPWO2017073767A1 (ja) * | 2015-10-30 | 2018-10-04 | 株式会社ボナック | ＴＧＦ−β１遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物 |
| WO2017073767A1 (ja) * | 2015-10-30 | 2017-05-04 | 株式会社ボナック | ＴＧＦ－β１遺伝子の発現を抑制する一本鎖核酸分子を安定に含有する組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20180363027A1 (en) | 2018-12-20 |
| US20100099149A1 (en) | 2010-04-22 |
| SG179454A1 (en) | 2012-04-27 |
| WO2008040126A1 (en) | 2008-04-10 |
| US10767215B2 (en) | 2020-09-08 |
| AU2007304776A1 (en) | 2008-04-10 |
| US10000795B2 (en) | 2018-06-19 |
| NZ576003A (en) | 2012-03-30 |
| EP2066686A4 (en) | 2010-07-14 |
| CA2664696A1 (en) | 2008-04-10 |
| JP2014057590A (ja) | 2014-04-03 |
| CA2664696C (en) | 2018-11-20 |
| EP2066686A1 (en) | 2009-06-10 |
| US20210198717A1 (en) | 2021-07-01 |
| US20160340713A1 (en) | 2016-11-24 |
| IL197916A0 (en) | 2009-12-24 |
| IL197916A (en) | 2016-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10767215B2 (en) | Stabilizing compositions and methods for extraction of ribonucleic acid | |
| Monteiro et al. | Detection of respiratory viruses in shelter dogs maintained under varying environmental conditions | |
| CN101175853A (zh) | 用于保存来自体液的核酸的组合物和方法 | |
| CN108546736A (zh) | 用于检测和鉴定生物样品中的核酸序列的组合物和方法 | |
| AU2013206564B2 (en) | Stabilizing compositions and methods for extraction of ribonucleic acid | |
| Khaliq et al. | Clinico-Hemato-Biochemical and Molecular Diagnostic Investigations of Peste des Petits Ruminants in Goats. | |
| RU2694499C1 (ru) | Тест-система для обнаружения генома возбудителя коронавирусной инфекции у крупного рогатого скота с помощью мультиплексной полимеразной цепной реакции с флуоресцентной детекцией в режиме реального времени | |
| Gabr et al. | Detection and genotyping of bovine viral diarrhea virus in cattle sera | |
| Dawson | Oral fluid as a non-invasive alternative diagnostic medium for disease monitoring in pigs | |
| Rennhofer et al. | Epidemiological investigations on coronavirus infections in dogs and cats in an animal shelter | |
| Buckle et al. | Detection of foot-and-mouth disease (FMD) virus in healthy cattle and buffalo at Southeast Asian slaughterhouses | |
| NL2027844B1 (en) | Kit for collecting saliva samples | |
| US20230349009A1 (en) | Kit for Collecting Saliva Samples | |
| Aziz et al. | The status, public response and challenges in overcoming emerging and exotic diseases—Nipah virus disease experience | |
| Henning et al. | The tropism of foot-and-mouth disease virus in African buffalo (Syncerus caffer) using BaseScope™ in situ hybridisation | |
| Armson | The use of milk for the surveillance of foot-and-mouth disease | |
| KR20240146187A (ko) | 크리스퍼-카스 시스템을 이용한 소 바이러스성 설사증 바이러스 검출방법 | |
| Sasidharan et al. | An optimized protocol for isolating Rhinosporidium seeberi sporangia from rhinosporidiosis tissue and extracting genomic DNA for next-generation sequencing | |
| Amoroso et al. | Fatal interstitial pneumonia caused by bovine coronavirus in cows from Southern Italy | |
| EP3971289A1 (en) | Kit for collecting samples | |
| BHAVANA | Master of Veterinary Science | |
| Sripiboon | Elephant Endotheliotropic Herpesvirus Infection inCaptive Asian Elephants (Elephas maximus) in Thailand: Implications for Conservation and Health Management | |
| Turcitu et al. | Preliminary results regarding bovine viral diarrhea virus epidemiology in Romanian wild boars | |
| Bowden | 15 Menangle Virus | |
| MS | MOLECULAR DETECTION AND HISTOPATHOLOGICAL STUDIES OF COMMON VIRAL RESPIRATORY INFECTIONS IN CHICKEN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100604 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111212 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120724 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121024 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130702 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131105 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131219 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20131225 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20140228 |